Blue Cross Blue Shield Iowa periurethral bulking coverage

Coverage and Medical Necessity Criteria

inv-01: Medically necessary periurethral bulking agents

Covered when ALL of the following are met

Eligibility: Individual has stress urinary incontinence (SUI)

Conservative therapy failure: Individual is unresponsive to conservative therapy for at least 3 months>=3 months

Conservative therapy may include pelvic floor muscle exercises, behavioral modifications (fluid management, weight loss, activity modification), pessary, intravaginal estrogen, or treatment of underlying causes

Agent selection: Treatment is with one of the following FDA-cleared periurethral bulking agents: Durasphere (carbon-coated spheres), Coaptite (calcium hydroxylapatite), Macroplastique (polydimethylsiloxane), or Bulkamid (polyacrylamide hydrogel)

Specific product names listed in policy

inv-02: Treatment failure and limits on additional sessions

Not covered when

Maximum sessions: No further treatment is considered medically necessary if the individual does not improve after 5 separate injection procedures>5 sessions

Further treatment beyond 5 sessions is considered treatment failure

Recurrence after successful treatment: Individuals with recurrent SUI after prior successful treatment may be considered for additional sessions if medical documentation supports benefit

Documentation must support prior response and timing (e.g., prior successful treatment 6-12 months previously)

inv-03: Investigational/noncovered agents

Investigational (not covered) when ANY of the following periurethral bulking agents are used

Autologous therapies: Autologous cellular therapies (myoblasts, fibroblasts, muscle-derived stem cells, adipose-derived stem cells), autologous fat, or autologous ear chondrocytes are investigational

Lack of clinical evidence demonstrating improved net health outcomes

Specific products investigational: Dextranomer/hyaluronic acid (Zuidex with Implacer) and polytetrafluoroethylene (Teflon) are investigational for SUI

Insufficient evidence of efficacy

inv-04: Trial-based coverage eligibility

Coverage is appropriate when ALL of the following trial-based conditions are met

Eligibility for bulking agent treatment: Clinical diagnosis of stress urinary incontinence (SUI) with objective baseline assessment (e.g., 24-hour pad test, provocation testing, or cough stress test).

Derived from RCT inclusion criteria

Prior conservative therapy documented: Prior attempt and inadequate response to conservative therapies (behavioral modification, pelvic floor muscle training, electrical stimulation, biofeedback, pessary, intravaginal estrogen, or other appropriate measures) documented, typically for at least 3 months.>=3 months

Trials often required prior conservative therapy and specified durations; document baseline severity and prior treatments

Patient counseling and expectations: Patient counseling that bulking agents often require repeat injections, may have limited durability compared with surgical options, and that retreatment is common.

inv-05: When surgical therapy may be preferred

Consider surgical alternatives when ANY of the following apply

Situations favoring surgery: Patient preference for higher objective and subjective cure rates (surgical procedures such as midurethral sling/tension-free vaginal tape have higher short-term efficacy than bulking agents).

Based on systematic reviews and RCTs showing superior subjective improvement with surgery

Failure of bulking therapy: Failure of bulking agent therapy (including repeat injections) to achieve desired symptom control

Consider surgical options when repeated injections are inadequate

Clinical characteristics or goals that prioritize durable long-term cure over less invasive treatment (e.g., expectation of durable long-term cure)

Guidance and trials indicate surgery may be preferred for more durable outcomes

inv-06: Covered Indications

Covered when consistent with guideline-recommended indications and evidence supports use of specific agents:

Primary coverage conditions: (1) Patient has symptomatic stress urinary incontinence; (2) bulking injection is being considered because the patient is not a candidate for or declines more invasive surgical procedures, or prior surgery failed or patient has recurrent symptoms; (3) the specific bulking agent has supportive evidence from RCTs or accepted professional guidance for use.

Derived from guideline statements and evidence summary noting bulking agents as options when surgery is unsuitable and some agents have RCT support

inv-07: Not Well-Established/Experimental Agents

Agents/uses considered investigational or insufficiently evidenced:

Not well supported agents: Agents with few RCTs or little evidence of efficacy (examples: autologous cellular therapy, autologous fat, autologous ear chondrocytes, polytetrafluoroethylene/Teflon) — coverage may be limited or denied absent stronger evidence.

Based on statement that few RCTs and little evidence exist for these agents

Use of periurethral bulking agents listed as investigational is considered not covered. Examples identified in the policy include autologous cellular therapies (e.g., myoblasts, fibroblasts, muscle-derived stem cells, adipose-derived stem cells), autologous fat, and autologous ear chondrocytes. The policy also identifies dextranomer/hyaluronic acid (Zuidex® with Implacer®) and polytetrafluoroethylene (Teflon®) as investigational for treatment of stress urinary incontinence (SUI) due to insufficient evidence of improved net health outcomes.

Autologous fat injections, autologous cellular therapies, autologous ear chondrocytes, and polytetrafluoroethylene (Teflon®) have limited or negative evidence for sustained effectiveness. A double-blind RCT found autologous fat was not more efficacious than placebo and reported a serious adverse event (pulmonary fat embolism). Autologous cellular therapy trials have produced mixed results including retracted data and randomized trials that failed to show a significant benefit versus placebo. No published clinical trials were identified for polytetrafluoroethylene as a bulking agent. Overall, the evidence for these agents is sparse and does not support routine coverage.

This portion of the document does not list any additional explicit exclusions beyond the investigational agents and not medically necessary conditions described elsewhere in the policy.

Further treatment with periurethral bulking agents after lack of improvement following 5 separate injection procedures is considered not medically necessary. Patients with recurrent SUI after prior successful treatment may be considered for additional sessions only if medical documentation supports prior response and timing (for example, prior successful treatment occurring ~6–12 months earlier).

Use of polytetrafluoroethylene (Teflon®), autologous fat, and autologous cellular therapies is not supported by robust evidence of sustained effectiveness. Trials have shown lack of benefit compared with placebo for some autologous materials and methodological or safety concerns (including a retracted RCT) have affected the body of evidence for autologous cellular therapies. Because of limited randomized data and safety signals, these agents are not supported as effective alternatives to established bulking agents.

Use of agents that lack evidence from randomized controlled trials or comparative studies may be considered not medically necessary due to insufficient evidence of efficacy. Examples noted in the policy include autologous cellular therapies, autologous fat, autologous ear chondrocytes, and polytetrafluoroethylene (Teflon®), for which there are few RCTs or little evidence of sustained benefit.

Billing and Procedure Codes

Codes table referencedmixed

No codes listed

No explicit codes in this document excerptmixed

No codes listed

Covered CPT CodesCPTCovered

51715

Endoscopic injection of implant material into the submucosal tissues of the urethra and/or bladder neck.

HCPCS CodesHCPCS

L8604	Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, urinary tract, 1 ml, includes shipping and necessary supplies.
L8606	Injectable bulking agent synthetic implant, urinary tract, 1 ml syringe, includes shipping and necessary supplies.

Responder definition

Responder definition≥50% reduction in urinary leakage (composite outcome used in RCTs, e.g., 24-hour pad test and ≥50% decrease in self-reported daily incontinence episodes)

Primary outcome timingMeasured at 12 months after final treatment in multiple trials

Measurement methodsObjective measures used in trials include 24-hour pad test and provocation testing (cough stress test)

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior Approval Required

Prior approval is not applicable for this policy.

Prior Authorization

Prior Authorization for Injectable Bulking Agents

Prior authorization is required for injectable periurethral bulking agents. Requests should document the diagnosis of stress urinary incontinence (SUI), failure or inadequate response to conservative therapy (see criteria), the specific bulking agent to be used, number of prior injection sessions and dates, and the proposed treatment plan. For members with recurrence after prior successful treatment, medical records must document prior response to the bulking agent and clinical rationale for additional sessions.

Confirm SUI diagnosis and prior conservative therapy attempts/duration (generally ≥ 3 months).
Document prior treatment sessions (dates and response).
Specify bulking agent and planned number of injections.

Background and Scope

Periurethral bulking agents are injectable substances placed into periurethral or submucosal tissues to increase tissue bulk, improve urethral coaptation, and increase resistance to urinary outflow with the goal of reducing stress urinary incontinence (SUI). They are typically injected as a liquid that forms a space-filling material and have been used primarily in adult women and, in some contexts, for postprostatectomy incontinence in men. Important clinical considerations include biocompatibility, durability of effect (benefit duration commonly ranges from approximately 3 to 12 months), potential need for repeat injections, and the relative effectiveness and safety compared with surgical options.

Key Definitions

Periurethral bulking agents

DefinitionInjectable substances placed periurethrally to increase tissue bulk and urethral resistance to treat urinary incontinence; injected as a liquid that solidifies into a spongy material

PurposeIncrease urethral coaptation and resistance to outflow to reduce stress urinary leakage

Product considerationsKey factors: biocompatibility, durability, and absence of migration

Stress urinary incontinence (SUI)

DefinitionInvoluntary leakage of urine with increases in intra-abdominal pressure (eg, coughing, sneezing, exercise)

PopulationPrimarily adult women; also used for postprostatectomy incontinence in men in some cases

OpenPayer

Periurethral Bulking Agents for the Treatment of Stress Urinary Incontinence

Coverage and Medical Necessity Criteria

Billing and Procedure Codes

Provider Requirements, Prior Authorization, and Documentation

Background and Scope

Key Definitions